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OBJECTIVE: NICE is currently developing clinical guidelines on
nutritional support in adults. The objective of this study was to
determine which patients in primary care in the UK were pre-
scribed enteral nutrition (sip & tube feeds) and to examine the
associated economic outcomes. METHODS: Patients prescribed
enteral nutrition during 2000/2001 were identiﬁed from the
General Practice Research Database (GPRD). The results were
analysed according to pre-determined BMI categories and diag-
nostic categories (cancer, dysphagia, stroke, GI, neurological,
respiratory disorders, cystic ﬁbrosis, renal disease, feeding difﬁ-
culties). Results for the two largest diagnostic groups (GI disor-
ders and cancer) are presented. RESULTS: In all, 2.34 million
patients were registered on GPRD. 13,153 patients (0.6%)
received >1 prescriptions for enteral nutrition, of whom 1332
had a recorded height and weight measurement. In all, 83% of
patients with GI disorders and 69% with cancer had a BMI
below 25. The number of nutritional prescriptions as a percent-
age of the total prescriptions by primary diagnosis category
(cancer and GI disorders respectively) were as follows: BMI
15–<20 (1.1%, 3.0%), 21–<25 (3.2%, 2.1%), 26–<30 (1.2%,
0.3%) and 31–<40 (0.5%, 0.4%). GP visits were frequent in
both diagnostic groups in all BMI categories (mean range 27–36
for GI disorders; 38–59 for cancer). Hospitalisations were also
frequent with means ranging from 2.5–3.0 for GI disorders;
1.9–4.6 for cancer, possibly reﬂecting severity of disease. CON-
CLUSIONS: It is expected that patients with a lower BMI would
have a higher percentage of nutritional prescriptions. Whilst this
was found to be the case for patients with GI disorders, the study
results showed that patients with cancer and a low BMI had
fewer nutritional prescriptions. This suggests that some patients
in the community who could beneﬁt from enteral nutrition may
not be receiving it.
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OBJECTIVES: No clinical guidelines or economic data exist on
the use of enteral nutrition (EN) for the UK. The aim of this
study was to determine which patients receive EN, and to 
estimate the relative economic burden of EN in the clinical 
management of such patients using observational databases.
METHODS: GPRD and CHKS datasets contain aggregated,
anonymised information on diagnoses, patient demographics
and resource use data in primary care (GPRD) and secondary
care (CHKS) settings. CHKS covered over 80 million episodes in
2001, representing 55% of UK hospitalisations. An average of
2,342,000 people were registered in the GPRD database in
2000/2001 representing 3.4% of the UK population. Patients
were identiﬁed using EN procedure OPCS-4 codes (CHKS) and
tube and sip feed drug codes (GPRD). Both databases were
analysed for comorbidities and resource use. RESULTS: From
the GPRD database (2000/2001), 13,153 patients received EN
of whom 1332 had a recorded height and weight measurement.
In the CHKS database there were 15,728 admissions in 2001
(<0.1% of all UK hospitalisations). Main diagnoses in both set-
tings were dysphagia, cancer, stroke, feeding difﬁculties and
anorexia and gastrointestinal disorders. Resource consumption
was high. The mean number of hospitalisations per patient was
2.24 and the mean number of nutritional prescriptions (tube and
sip feeds) annually in primary care was 5.8. However, the costs
of daily tube feeds (£10.20–£13.18) represented less than 4% 
of daily inpatient costs. CONCLUSIONS: Although 40% of
patients in UK hospitals and 11% in the community are mal-
nourished, very few are nutritionally assessed in order to receive
EN. The economic burden of EN remains low compared to the
overall patient management. This is also one of the ﬁrst obser-
vational database studies which has aimed to estimate resource
use across both primary and secondary care settings.
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Increased expenditures for pharmaceuticals in previous years
lead to implementation of several cost-containment measures in
2003 in the Slovak Republic. Within that, co-payments for
antibiotic drugs were increased from 0 to 1.25€ per package in
2002 and in the beginning of 2003 from 0 to 5€ per package
after November, 2003. The consumption of antibiotics signiﬁ-
cantly decreased from November 2003 compared to the same
period the previous year. OBJECTIVES: To assess the inﬂuence
of increased co-payment of antibiotic agents to their decreased
consumption in a retrospective study. METHODS: Consumption
of antibiotic agents (group J01 according to ATC classiﬁcation)
prescribed in outpatient care in the Slovak Republic during the
period of November, 2003 to April, 2004 was compared to con-
sumption during November, 2002 to April, 2003. Antibiotics
were divided into three groups according to the level of co-
payment: without increased co-payment, with slightly increased
and signiﬁcantly increased co-payment. RESULTS: Overall con-
sumption in period 2003–2004 decreased by 25.1% compared
to the previous year. Consumption was 46.5% lower in the
group with the highest increase of co-payment, but only 30.9%
or 13.8% lower in the group with slightly increased co-payment
and in the group without change in co-payment, respectively.
CONCLUSIONS: Increase in co-payment in November, 2003
had a huge effect on the use of antibiotic agents in the Slovak
Republic. Although 55% of antibiotic agents had no change in
the level of co-payment, the consumption decreased in this group
by 13.8%, probably because of awareness of increased co-
payments within this group of pharmaceuticals.
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OBJECTIVES: The FDA is tasked with the evaluation of medical
devices to determine the products’ safety and effectiveness. Uti-
lization of patient-reported outcome (PRO) measures for medical
device therapies poses special methodological challenges, due to
small sample sizes and the often unblinded study design of device
clinical trials. However, PRO’s might prove useful in special cir-
